Birtamimab in AL Amyloidosis: Key Takeaways from the Phase III VITAL Trial
Drs. Kumar and Zonder discuss results from the Phase III Vital trial investigating birtamimab and key takeaways.
EP: 1.AL Amyloidosis: Background, Patient Profile, and Staging
EP: 2.Navigating the Differential Diagnosis of AL Amyloidosis
EP: 3.Treatment Approaches in AL Amyloidosis
EP: 4.Limitations of Available Treatment Options for Patients with Cardiac Involvement
Now Viewing
EP: 5.Birtamimab in AL Amyloidosis: Key Takeaways from the Phase III VITAL Trial
EP: 6.Birtamimab Safety Profile in the VITAL Study
EP: 7.Adverse Event Management in AL Amyloidosis
EP: 8.Ongoing AFFIRM-AL Trial Background, Patient Eligibility, and Active Enrollment
EP: 9.Revolutionizing the AL Amyloidosis Treatment Paradigm: Novel Agents and Combination Approaches
EP: 10.Clinical Pearls and Future Directions in AL Amyloidosis
Related Videos
Related Content
